A collaborative study conducted across cancer treatment centers in the United States has identified malignant brain tumors as the most common cause of cancer-related deaths in adolescents and young adults aged 15 to 39 years.
A collaborative study conducted across cancer treatment centers in the United States, and funded by the American Brain Tumor Association (ABTA), has identified malignant brain tumors as the most common cause of cancer-related deaths in adolescents and young adults (AYAs) aged 15 to 39 years, and the most common cancer diagnosed among 15 to 19 year olds.
The detailed study, published in the journal Neuro-Oncology, conducted a retrospective analysis of data from the Central Brain Tumor Registry of the United States, gathered between 2008 and 2012.
Based on their analysis, the authors found that while brain and central nervous system (CNS) tumors were the most common type of cancer in the 15-19 age group, incidence of other cancers increased with age, such that among the oldest AYA age group, brain and CNS tumors followed breast and thyroid cancer in frequency of occurrence.
Some of the other findings from the study include:
o Incidence of primary brain and CNS tumors is lowest in New England and the Pacific regions and highest in the Middle Atlantic regions.
o Incidence of malignant primary brain and CNS tumors is lowest in the Pacific and South Atlantic and highest in West North Central and Middle Atlantic regions.
o Incidence of non-malignant primary brain and CNS tumors is lowest in New England and Pacific and highest in Mountain and West South Central regions.
o is higher in males than in females, and the gap increases with age
o is highest in the West North Central and Esast South Central regions and lowest in the New England, Middle Atlantic, and South Atlantic regions.
Interestingly, the tumor subtypes vary between AYAs and adult patients—meningiomas and glioblastomas are common among adults while younger patients present with much more diversity. The study also reported a transition from premalignant to and low-grade tumors in the younger AYA patients, to predominantly high-grade tumors with increasing age.
Elizabeth Wilson, president and CEO of the ABTA said in a statement, “For these individuals—who are finishing school, pursuing their careers and starting and raising young families—a brain tumor diagnosis is especially cruel and disruptive. This report enables us for the first time to zero-in on the types of tumors occurring at key intervals over a 25-year time span to help guide critical research investments and strategies for living with a brain tumor that reflect the patient’s unique needs.”
According to the study, more than 10,000 cases of brain and CNS tumors are diagnosed in the AYA population, which is responsible for about 434 deaths annually.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More